Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

[11] Fontana GA(2022)Efficacy and safety of gefapixant, a P2X(3) receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials Lancet 399 691-49

[12] Sovijarvi AR(2020)Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial Lancet Respir Med 8 38-412

[13] Pistolesi M(2022)Gefapixant: first approval Drugs 82 406-undefined

[14] Chung KF(2009)Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion Pharm Stat 8 undefined-undefined

[15] Widdicombe J(2022)Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans Pharmacol Res Perspect 10 undefined-undefined

[16] O'Connell F(2022)Assessment of pharmacokinetic interaction between gefapixant (MK-7264), a P2X3 receptor antagonist, and the OATP1B1 drug transporter substrate pitavastatin Clin Pharmacol Drug Dev 11 undefined-undefined

[17] Geppetti P(undefined)undefined undefined undefined undefined-undefined

[18] Gronke L(undefined)undefined undefined undefined undefined-undefined

[19] De Jongste J(undefined)undefined undefined undefined undefined-undefined

[20] Smith JA(undefined)undefined undefined undefined undefined-undefined

[11] Fontana GA(2022)Efficacy and safety of gefapixant, a P2X(3) receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials Lancet 399 691-49

[12] Sovijarvi AR(2020)Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial Lancet Respir Med 8 38-412

[13] Pistolesi M(2022)Gefapixant: first approval Drugs 82 406-undefined

[14] Chung KF(2009)Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion Pharm Stat 8 undefined-undefined

[15] Widdicombe J(2022)Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans Pharmacol Res Perspect 10 undefined-undefined

[16] O'Connell F(2022)Assessment of pharmacokinetic interaction between gefapixant (MK-7264), a P2X3 receptor antagonist, and the OATP1B1 drug transporter substrate pitavastatin Clin Pharmacol Drug Dev 11 undefined-undefined

[17] Geppetti P(undefined)undefined undefined undefined undefined-undefined

[18] Gronke L(undefined)undefined undefined undefined undefined-undefined

[19] De Jongste J(undefined)undefined undefined undefined undefined-undefined

[20] Smith JA(undefined)undefined undefined undefined undefined-undefined